Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Summary: This study explored how the drug ipamorelin, which stimulates growth hormone release, behaves in the body and affects hormone levels in healthy male volunteers. The results showed that ipamorelin causes a dose-dependent, short-duration release of growth hormone and helped develop a model to predict its effects at different dosages.

Link: PubMed

Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

Summary: This study tested the safety and effectiveness of the drug ipamorelin in treating postoperative ileus in patients undergoing bowel surgery and found it to be well-tolerated. However, ipamorelin did not show significant improvements over the placebo in helping patients tolerate their first solid meal after surgery.

Link: PubMed

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males

Summary: Male hypogonadism is a growing concern that negatively impacts quality of life, with obesity and metabolic syndrome both contributing to and resulting from this condition. While testosterone is the standard treatment, new therapies like growth hormone secretagogues (GHS) are being explored for their potential benefits in improving body composition and alleviating symptoms, though more research is needed to fully understand their effectiveness.

Link: PubMed

Detection of the synthetic peptide ipamorelin in dried blood spots by means of UHPLC-HRMS

Summary: Researchers developed a new method using ultra high pressure liquid chromatography–high resolution mass spectrometry to detect the growth hormone-releasing peptide, ipamorelin, in dried blood spots. This approach, which is easy and minimally invasive, proved to be sensitive and accurate, making it promising for clinical monitoring and anti-doping tests.

Link: ScienceDirect

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

Summary: Ipamorelin, a new synthetic peptide, was found to significantly increase longitudinal bone growth rate and body weight in a dose-dependent manner when administered to adult female rats over 15 days. The study showed that while ipamorelin effectively boosted growth hormone-related measures, it did not alter key bone formation markers or pituitary growth hormone content, suggesting potential for future use in treating growth retardation in children.

Link: ScienceDirect

The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats

Summary: This study investigated whether the compound Ipamorelin could mitigate the muscle and bone weakening effects of the steroid methylprednisolone in rats. Results showed that combining Ipamorelin with the steroid significantly improved muscle strength and bone formation compared to using the steroid alone.

Link: ScienceDirect

Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats

Summary: The study investigated the effects of Ipamorelin and Growth Hormone (GH) on liver nitrogen metabolism in steroid-treated rats, finding that both substances countered the negative catabolic effects caused by prednisolone. While GH and Ipamorelin both improved nitrogen balance and normalized urea cycle activity, GH was more effective than Ipamorelin at the given doses.

Link: ScienceDirect

A New Series of Highly Potent Growth Hormone-Releasing Peptides Derived from Ipamorelin

Summary: Researchers developed new compounds related to the growth hormone (GH) secretagogue ipamorelin, aiming to improve oral bioavailability by reducing molecular size and hydrogen-bonding sites. One compound, NNC 26-0235, demonstrated significant effectiveness in increasing GH levels both in vitro and in vivo, showing promising oral bioavailability in dogs and rats, although another compound, NNC 26-0323, had moderate in vitro effect but better oral absorption in rats.

Link: Departments of Medicinal Chemistry Research, Assay and Cell Technology

The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats

Summary: This study found that treating young adult female rats with growth hormone secretagogues ipamorelin and GHRP-6 increased their bone mineral content (BMC) and body weight. However, while bone size and weight increased, the density of the bones (volumetric BMD) remained unchanged.

Link: Journal of Endocrinology